147 related articles for article (PubMed ID: 28811252)
1. Expression of ALCAM (CD166) and PD-L1 (CD274) independently predicts shorter survival in malignant pleural mesothelioma.
Inaguma S; Lasota J; Wang Z; Czapiewski P; Langfort R; Rys J; Szpor J; Waloszczyk P; Okoń K; Biernat W; Ikeda H; Schrump DS; Hassan R; Miettinen M
Hum Pathol; 2018 Jan; 71():1-7. PubMed ID: 28811252
[TBL] [Abstract][Full Text] [Related]
2. V-domain Ig-containing suppressor of T-cell activation (VISTA), a potentially targetable immune checkpoint molecule, is highly expressed in epithelioid malignant pleural mesothelioma.
Muller S; Victoria Lai W; Adusumilli PS; Desmeules P; Frosina D; Jungbluth A; Ni A; Eguchi T; Travis WD; Ladanyi M; Zauderer MG; Sauter JL
Mod Pathol; 2020 Feb; 33(2):303-311. PubMed ID: 31537897
[TBL] [Abstract][Full Text] [Related]
3. Thoracic mesenchymal malignant tumors and programed cell death ligand-1 status: Clinicopathologic and prognostic analysis of eight pulmonary sarcomatoid carcinomas and eight malignant mesotheliomas.
Otsubo K; Sakai H; Kimura H; Miyazawa T; Marushima H; Kojima K; Furuya N; Mineshita M; Chosokabe M; Koike J; Saji H
Thorac Cancer; 2021 Dec; 12(23):3169-3176. PubMed ID: 34655161
[TBL] [Abstract][Full Text] [Related]
4. Higher concordance of PD-L1 expression between biopsies and effusions in epithelioid than in nonepithelioid pleural mesothelioma.
Mansour MSI; Seidal T; Mager U; Dobra K; Brunnström H; Dejmek A
Cancer Cytopathol; 2021 Jun; 129(6):468-478. PubMed ID: 33493383
[TBL] [Abstract][Full Text] [Related]
5. Mesothelin expression remodeled the immune-matrix tumor microenvironment predicting the risk of death in patients with malignant pleural mesothelioma.
Qualiotto AN; Baldavira CM; Balancin M; Ab'Saber A; Takagaki T; Capelozzi VL
Front Immunol; 2023; 14():1268927. PubMed ID: 37901248
[TBL] [Abstract][Full Text] [Related]
6. Effects of tumor-infiltrating CD8+ T cells, PD1/PD-L1 axis, and expression patterns of HLA class I on the prognosis of patients with malignant pleural mesothelioma who underwent extra-pleural pneumonectomy.
Okita R; Mimura-Kimura Y; Kawamoto N; Yamamoto N; Umeda M; Okada M; Inokawa H; Mimura Y; Murakami T; Nakata M; Okabe K
Cancer Immunol Immunother; 2023 Apr; 72(4):865-879. PubMed ID: 36115921
[TBL] [Abstract][Full Text] [Related]
7. LAG3 is an independent prognostic biomarker and potential target for immune checkpoint inhibitors in malignant pleural mesothelioma: a retrospective study.
Arimura K; Hiroshima K; Nagashima Y; Nakazawa T; Ogihara A; Orimo M; Sato Y; Katsura H; Kanzaki M; Kondo M; Tagaya E
BMC Cancer; 2023 Dec; 23(1):1206. PubMed ID: 38062416
[TBL] [Abstract][Full Text] [Related]
8. PD-1-expressing macrophages and CD8 T cells are independent predictors of clinical benefit from PD-1 inhibition in advanced mesothelioma.
Homicsko K; Zygoura P; Norkin M; Tissot S; Shakarishvili N; Popat S; Curioni-Fontecedro A; O'Brien M; Pope A; Shah R; Fisher P; Spicer J; Roy A; Gilligan D; Rusakiewicz S; Fortis E; Marti N; Kammler R; Finn SP; Coukos G; Dafni U; Peters S; Stahel RA
J Immunother Cancer; 2023 Oct; 11(10):. PubMed ID: 37880184
[TBL] [Abstract][Full Text] [Related]
9. A Phase II Window of Opportunity Study of Neoadjuvant PD-L1 versus PD-L1 plus CTLA-4 Blockade for Patients with Malignant Pleural Mesothelioma.
Lee HS; Jang HJ; Ramineni M; Wang DY; Ramos D; Choi JM; Splawn T; Espinoza M; Almarez M; Hosey L; Jo E; Hilsenbeck S; Amos CI; Ripley RT; Burt BM
Clin Cancer Res; 2023 Feb; 29(3):548-559. PubMed ID: 36469573
[TBL] [Abstract][Full Text] [Related]
10. Clinical Outcomes Associated With Pembrolizumab Monotherapy Among Adults With Diffuse Malignant Peritoneal Mesothelioma.
Marmarelis ME; Wang X; Roshkovan L; Grady CB; Miura JT; Ginsberg MS; Ciunci CA; Egger J; Walker S; Cercek A; Foote MB; Litzky LA; Nash G; Haas AR; Karakousis GC; Cengel KA; Katz SI; Zauderer MG; Langer CJ; Offin M
JAMA Netw Open; 2023 Mar; 6(3):e232526. PubMed ID: 36897589
[TBL] [Abstract][Full Text] [Related]
11. Pleural mesothelioma metastasis of the scalp.
Bicak T; Ozekinci S; İbiloğlu İ
Pol J Pathol; 2023; 74(4):297-301. PubMed ID: 38477094
[TBL] [Abstract][Full Text] [Related]
12. DCLK1 is correlated with MET and ERK5 expression, and associated with prognosis in malignant pleural mesothelioma.
Wang H; Dai YY; Zhang WQ; Hsu PC; Yang YL; Wang YC; Chan G; Au A; Xu ZD; Jiang SJ; Wang W; Jablons DM; You L
Int J Oncol; 2017 Jul; 51(1):91-103. PubMed ID: 28560410
[TBL] [Abstract][Full Text] [Related]
13. Anti-PD1 does not improve pyroptosis induced by γδ T cells but promotes tumor regression in a pleural mesothelioma mouse model.
Lui KS; Ye Z; Chan HC; Tanaka Y; Cheung AKL
Front Immunol; 2023; 14():1282710. PubMed ID: 38077396
[TBL] [Abstract][Full Text] [Related]
14. Tumour cell PD-L1 expression is prognostic in patients with malignant pleural effusion: the impact of C-reactive protein and immune-checkpoint inhibition.
Ghanim B; Rosenmayr A; Stockhammer P; Vogl M; Celik A; Bas A; Kurul IC; Akyurek N; Varga A; Plönes T; Bankfalvi A; Hager T; Schuler M; Hackner K; Errhalt P; Scheed A; Seebacher G; Hegedus B; Stubenberger E; Aigner C
Sci Rep; 2020 Apr; 10(1):5784. PubMed ID: 32238865
[TBL] [Abstract][Full Text] [Related]
15. Molecular and immunological features of a prolonged exceptional responder with malignant pleural mesothelioma treated initially and rechallenged with pembrolizumab.
Minchom A; Yuan W; Crespo M; Gurel B; Figueiredo I; Wotherspoon A; Miranda S; Riisnaes R; Ferreira A; Bertan C; Pereira R; Clarke M; Baker C; Ang JE; Fotiadis N; Tunariu N; Carreira S; Popat S; O'Brien M; Banerji U; de Bono J; Lopez J
J Immunother Cancer; 2020 Mar; 8(1):. PubMed ID: 32169873
[TBL] [Abstract][Full Text] [Related]
16. High tumor cell platelet-derived growth factor receptor beta expression is associated with shorter survival in malignant pleural epithelioid mesothelioma.
Ollila H; Paajanen J; Wolff H; Ilonen I; Sutinen E; Välimäki K; Östman A; Anttila S; Kettunen E; Räsänen J; Kallioniemi O; Myllärniemi M; Mäyränpää MI; Pellinen T
J Pathol Clin Res; 2021 Sep; 7(5):482-494. PubMed ID: 33955203
[TBL] [Abstract][Full Text] [Related]
17. Prognostic impact of PD-1 and PD-L1 expression in malignant pleural mesothelioma: an international multicenter study.
Brcic L; Klikovits T; Megyesfalvi Z; Mosleh B; Sinn K; Hritcu R; Laszlo V; Cufer T; Rozman A; Kern I; Mohorcic K; Jakopovic M; Samarzija M; Seiwerth S; Kolek V; Fischer O; Jakubec P; Škarda J; Gieszer B; Hegedus B; Fillinger J; Renyi-Vamos F; Buder A; Bilecz A; Berger W; Grusch M; Hoetzenecker K; Klepetko W; Hoda MA; Filipits M; Dome B
Transl Lung Cancer Res; 2021 Apr; 10(4):1594-1607. PubMed ID: 34012777
[TBL] [Abstract][Full Text] [Related]
18. P14/ARF-Positive Malignant Pleural Mesothelioma: A Phenotype With Distinct Immune Microenvironment.
Pezzuto F; Lunardi F; Vedovelli L; Fortarezza F; Urso L; Grosso F; Ceresoli GL; Kern I; Vlacic G; Faccioli E; Schiavon M; Gregori D; Rea F; Pasello G; Calabrese F
Front Oncol; 2021; 11():653497. PubMed ID: 33828993
[TBL] [Abstract][Full Text] [Related]
19. Significant co-expression of putative cancer stem cell markers, EpCAM and CD166, correlates with tumor stage and invasive behavior in colorectal cancer.
Kalantari E; Taheri T; Fata S; Abolhasani M; Mehrazma M; Madjd Z; Asgari M
World J Surg Oncol; 2022 Jan; 20(1):15. PubMed ID: 35016698
[TBL] [Abstract][Full Text] [Related]
20. PD-L1 expression complements CALGB prognostic scoring system in malignant pleural mesothelioma.
Avilés-Salas A; Cabrera-Miranda L; Hernández-Pedro N; Vargas-Lías DS; Samtani S; Muñoz-Montaño W; Motola-Kuba D; Corrales-Rodríguez L; Martín C; Cardona AF; Palomares-Palomares CB; Arrieta O
Front Oncol; 2023; 13():1269029. PubMed ID: 38111532
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
